Dr. Lal Pathlabs Limited
₹1,906.30-₹7.00 (-0.4%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹23,777 Cr
- P/E
- 45.0x
- EV / EBITDA
- 38.3x
- Revenue
- ₹2,352 Cr
- Net margin
- 19.5%
- ROCE
- 27.5%
Price chart
Technical chartScreen technicals →+23.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -4.1%
- 3M
- +1.5%
- 6M
- +39.3%
- 1Y
- +23.4%
- 5Y
- +4.8%
52-week range
Day change -₹7.00 (-0.4%) from ₹1,913 to ₹1,906 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in LALPATHLAB, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 20.2%
Concerns0
Rule-based from financial data. Not advice.
About the company
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
- Sector
- Healthcare
- Shares outstanding
- 16.7 Cr shares
- ISIN
- INE600L01024
- BSE code
- 539524
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹23,777 Cr
- P/E
- 45.0x
- P/B
- 10.2x
- EV / EBITDA
- 38.3x
- EV / Sales
- 12.1x
- P/S
- 12.1x
- Earnings yield
- 2.2%
- 52-week high
- ₹2,006.55
- 52-week low
- ₹1,306.50
Profitability
- Operating margin
- 28.4%
- Net margin
- 19.5%
- EBITDA margin
- 31.5%
- ROE
- 20.2%
- ROCE
- 27.5%
- ROA
- 15.9%
- Dividend payout
- 52.0%
- Tax rate
- 26.0%
- Other income, % of PBT
- 11.6%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,352 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.1%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹619 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 21.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 29.4%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.5%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹478 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹78.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.1%
Solvency and efficiency
- Current ratio
- 5.44
- Debt / Equity
- 0.07
- Debt / Assets
- 0.06
- Debt / EBITDA
- 0.22
- Interest coverage
- 20.70
- Financial leverage
- 1.27
- CFO / Net profit
- 1.24
- Cash / Market cap
- 3.9%
- Cash per share
- ₹55.22
- Asset turnover
- 0.81
- Fixed asset turnover
- 5.73
- Capital intensity
- 0.17
- Debtor days
- 14 days
- Inventory turnover
- 14.04
- Cash conversion cycle
- -116 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹21 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,684 Cr |
| Sales | Operating profit | ₹668 Cr |
| Operating profit | Interest | ₹22 Cr |
| Operating profit | Depreciation | ₹134 Cr |
| Operating profit | Profit before tax | ₹512 Cr |
| Other income | Profit before tax | ₹109 Cr |
| Profit before tax | Tax and other | ₹124 Cr |
| Profit before tax | Net profit | ₹497 Cr |
Revenue and net profit
Revenue grew 19.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,491 Cr | ₹280 Cr |
| FY2022 | ₹1,873 Cr | ₹344 Cr |
| FY2023 | ₹1,769 Cr | ₹292 Cr |
| FY2024 | ₹1,967 Cr | ₹384 Cr |
| FY2025 | ₹2,352 Cr | ₹497 Cr |
Cash flows
FY2025: ₹540 Cr from operations, ₹247 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹373 Cr | ₹178 Cr |
| FY2022 | ₹424 Cr | -₹24 Cr |
| FY2023 | ₹428 Cr | ₹140 Cr |
| FY2024 | ₹478 Cr | ₹510 Cr |
| FY2025 | ₹540 Cr | ₹247 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹2,352 Cr+19.6%1Y
- Net profit
- ₹497 Cr+29.4%1Y
- Cash from operations
- ₹540 Cr
- Free cash flow
- ₹247 Cr-51.6%1Y
- Revenue CAGR, 5Y
- 9.1%
- EBITDA CAGR, 5Y
- 9.9%
- Net profit CAGR, 5Y
- 11.5%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹2,352 Cr | ₹668 Cr | — | ₹497 Cr | ₹540 Cr | ₹247 Cr | 23.3% | +19.6% | +29.4% |
Monthly returns
Month-by-month returns of LALPATHLAB across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,621 Cr |
| Equity capital | ₹84 Cr |
| Reserves | ₹2,051 Cr |
| Borrowings | ₹53 Cr |
| Other liabilities | ₹434 Cr |
| Assets | ₹2,621 Cr |
| Fixed assets | ₹1,051 Cr |
| Capital work in progress | ₹3 Cr |
| Investments | ₹416 Cr |
| Other assets | ₹1,151 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
LALPATHLAB trades at 45.0x earnings against a peer median of 52.6x (a 14% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs LimitedLALPATHLABthis companyP/E ↓ discount | ₹23,777 Cr | 45.0x | 10.2x | 20.2% | 38.3x |
| Syngene International LimitedSYNGENE | ₹25,375 Cr | 58.0x | 5.5x | 11.1% | 26.5x |
| Krishna Institute of Medical Sciences LimitedKIMS | ₹24,919 Cr | 87.7x | 10.9x | 12.6% | 65.6x |
| Pine Labs LimitedPINELABS | ₹24,711 Cr | 442.0x | — | -9.1% | 164.0x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| PIRAMAL PHARMA LIMITEDPPLPHARMA | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Onesource Specialty Pharma LimitedONESOURCE | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
LALPATHLAB since 1 January, against earlier years.
Historical volatility
LALPATHLAB's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 27.0% |
| FY2022 | 27.0% |
| FY2023 | 26.0% |
| FY2024 | 28.0% |
| FY2025 | 28.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹2,352 Cr |
| Costs | |
| Interest | ₹22 Cr |
| Expenses | ₹1,684 Cr |
| Operating profitOperating Profit | ₹668 Cr |
| Other income and charges | |
| Profit before tax | ₹621 Cr |
| Tax | |
| Net profitNet Profit | ₹497 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,621 Cr |
| Equity capitalEquity Capital | ₹84 Cr |
| Reserves | ₹2,051 Cr |
| Borrowings | ₹53 Cr |
| Other liabilitiesOther Liabilities | ₹434 Cr |
| AssetsTotal Assets | ₹2,621 Cr |
| Fixed assetsFixed Assets | ₹1,051 Cr |
| Capital work in progressCWIP | ₹3 Cr |
| Investments | ₹416 Cr |
| Other assetsOther Assets | ₹1,151 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹540 Cr |
| Investing cash flowCash from Investing Activity | -₹293 Cr |
| Financing cash flowCash from Financing Activity | -₹325 Cr |
| Change in cashNet Cash Flow | -₹78 Cr |
Learn while you research
Academy chapters picked for Dr. Lal Pathlabs Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 45.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read